Pharma's Market
SPECIAL REPORT
MOST SHARED
- Greek Political Leaders Agree on Bailout Reforms
- Jobless Claims Drop 15,000, Stay on Downward Trek
- US Jobs Gap Between Young and Old Is Widest Ever
- What's Shaking: Thursday's Early Movers
- Premium Commanded by Whole Foods Ridiculous, or Surprisingly Modest?
- Pepsico to Cut 8,700 Jobs; Quarterly Earnings Rise
- A Greek Deal, but What Is the Deal?
- Take That: Best Tax Breaks to Grab Now
- States Negotiate $26 Billion Deal for Homeowners
- Zuckerberg Takes Control, You Get $100
- China’s Steelmakers Set for Turnaround: Analyst
- Bulls Bet Silicon Motion Will Bounce
- News Corp. Beats Estimates on Studio, Cable Strength
- Bindi: Charm is Not Enough for Italy's Prime Minister Mario Monti
- Tobacco Stocks a Hot Dividend Play: Analyst
- Is Apple Coming to Sam’s Club Stores?
- Gas Prices in All 50 States Back Above $3 a Gallon
- Is America Ready for a Bacon Milkshake?
- As Mortgage Refinancings Surge, Banks Struggle
- Greek Political Leaders Agree On Austerity Reforms
- ECB Holds Rate, Relaxes Rules for Long-Term Loans
- Wholesale Trade Up 1 Percent in December
- Jobless Claims Drop 15,000, Stay on Downward Trek
- States Negotiate $26 Billion Deal for Homeowners
- Two Top Ford Executives Set to Retire
- 12 Unique Dating Sites
- Bank of England to Print More Money to Boost Recovery
- White House's Jobs Forecast Out of Date as It's Issued
RSS FEED
» Help
Tamiflu Turnaround
By: Mike Huckman
Reporter
Reporter
![]() |
AP |
Roche today is announcing that it's cutting back production of Tamiflu. When bird flu stories and fears started reaching critical mass more than a year ago, Roche came under considerable criticism for not being able to make enough Tamiflu to meet the sudden spike in demand.
The drug has been shown to work in fighting off seasonal and avian flu strains, but there are scattered reports of patient resistance to Tamiflu. Roche responded by quickly expanding its worldwide manufacturing capacity. Soon after, it announced that it could make as much as 400 million courses of Tamiflu per year. (Gilead Sciences [GILD Loading... ()
But to date, Roche says it has received orders from governments, health agencies and corporations for a total of 215 million courses. So it's scaling back unless or until demand picks up. I suspect that could happen if or when an infected bird is confirmed to have shown up on North American shores.
GlaxoSmithKline [GSK Loading... ()
Questions? Comments?
© 2012 CNBC, Inc. All Rights Reserved











